ログアウト
ライト
ダーク
戻る
-
マーケット
-
注目機能
-
ニュース
-
Moo
-
学ぶ
-
もっと見る
- 日本語
- ダーク
- ライト
センセイ・バイオセラピューティクスに関するコメント
Biotherapeutics Company Announces Revolutionary Cancer Treatment Development
In the ongoing battle against cancer, groundbreaking research and innovative treatments are the beacons of hope for patients worldwide. One such beacon shines brightly from the laboratories of Sensei Biotherapeutics, Inc., a clinical-stage immuno-oncology company dedicated to the discovery and development of next-gen...
NEWS
Sensei Biotherapeutics, Inc. (SNSE) announces the publication of a research paper in Nature Communications detailing the development of SNS-101, a pH-sensitive monoclonal antibody targeting VISTA to suppress T-cell activation in cancer patients. The paper highlights the unique mechanism of SNS-101 in mitigating CRS risk and maintaining a favorable safety profile, potentially revolutionizing VISTA-directed immunotherapy.
Interesting News
👀
コラムUS Top Rating Updates on 10/3: WFC, ADBE, MU, STX and More
• $ボックス(BOX.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $34 (from $32)
• $CFインダストリーズ・ホールディングス(CF.US)$: RBC Capital Upgrades to Outperform from Sector Perform - PT $135 (from $110)
• $ニュー・ゴールド(NGD.US)$: RBC Capital Upgrades to Outperform from Sector Perform - PT $1.25 (from $1)
• $センセイ・バイオセラピューティクス(SNSE.US)$: Oppenheimer Upgrades to Outperform from Perform - PT $5
• $Senetas Corp Ltd(SEN.AU)$ : Tru...
まだコメントはありません